Caption Management’s Aimmune Therapeutics AIMT Stock Holding History

Caption Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-27,500	Closed	-$948K	–	1366
2020 Q3	$948K	Sell	27,500 -2,500	-8%	-$53.2K	0.02%	632
2020 Q2	$501K	Buy	+30,000	New	+$509K	0.02%	669
2019 Q4	–	Sell	-30,000	Closed	-$628K	–	1079
2019 Q3	$628K	Buy	+30,000	New	+$612K	0.03%	459

Caption Management's AIMT Position: Q1 2020 in Review

Caption Management sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 5,000 shares — an estimated $167K sold.

Caption Management first reported a position in AIMT in Q3 2018 and held it in 3 quarters. The position peaked at $593K in Q4 2018. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

Caption Management reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
Caption Management sold 5,000 Aimmune Therapeutics shares in Q1 2020, an estimated $167K.
Caption Management first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 3 quarters.
Caption Management's Aimmune Therapeutics position peaked at $593K in Q4 2018.
161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Caption Management's 13F filing for Q1 2020, filed 15 May 2020.